[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyspnea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyspnea":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,47,77,118,150,176,207,230,265,300,322,354,377,398,420,447,472,500,522,552,578,602,628,652,679],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642257","contactless-ultrasound-data-acquisition-in-emergency-departments-to-discriminate-the-origin-of-dyspnea-and-chest-pain-100642257",false,"NCT07653204","Contactless Ultrasound Data Acquisition in Emergency Departments to Discriminate the Origin of Dyspnea and Chest Pain","Prospective Study for Data Acquisition in Emergency Departments to Develop a Discrimination Algorithm for the Origin of Dyspnea and Chest Pain Using the ADx-One Medical Device","PAnDA-One","Inclusion Criteria:\n\n* Presentation to the emergency department for one or more of the following symptoms of less than 14 days' duration: acute non-traumatic dyspnea, or recent worsening of chronic dyspnea, or non-traumatic chest pain.\n* Patient able to sit on a chair or on the edge of the bed\n* Affiliation to national health insurance\n* Able to receive study information, understand the study, and provide written informed consent\n\nExclusion Criteria:\n\n* • Immediate need for life-saving intervention or clinical instability incompatible with study procedures.\n\n  * Shock or severe hemodynamic instability, for example systolic blood pressure \\\u003C90 mmHg for at least 30 minutes or associated signs of hypoperfusion.\n  * Altered mental status or any condition preventing provision of valid informed consent.\n  * Known cognitive impairment preventing informed consent.\n  * Transfer to another care site before the ADx-One acquisition can be performed.\n  * Known pregnancy\n  * Minor, legally protected adult, or person deprived of liberty.\n  * Participation in another interventional clinical study judged incompatible with this study.","ALL","18 Years",{"count":21,"type":22},2500,"ESTIMATED","OBSERVATIONAL","PAnDA-One is a prospective, multicenter, interventional study (10 centers, France) aimed at developing and validating a diagnostic support algorithm based on the ADx-One medical device, which non-invasively acquires thoracic vibrations using airborne ultrasound.\n\nThe study will enroll 2,500 patients presenting to the emergency department with acute dyspnea or non-traumatic chest pain, divided into a development cohort (N = 1,500) and an independent test cohort (N = 1,000). The deep learning algorithm will be trained to discriminate cardiovascular from non-cardiovascular origins of symptoms, and its performance will be assessed by AUROC, sensitivity, and specificity against a final diagnosis established by an expert adjudication committee.\n\nPatient management will not be modified by study participation.",[26,27],"Dyspnea","Chest Pain",[29,30,31,32,33],"airborne ultrasound","dyspnea","chest pain","emergency department","algorithm","NOT_YET_RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":22},"2026-09",{"date":42,"type":22},"2027-05",{"name":44,"class":45},"Austral Diagnostics","INDUSTRY",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100447225","ventilationperfusion-petct-with-galligas-and-68ga-maa-for-regional-lung-function-assessment-after-pulmonary-embolism-100447225","NCT05103670","Ventilation\u002FPerfusion PET\u002FCT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism","EOLE","Inclusion Criteria:\n\n* Patient included in the RAMBO study, whose inclusion criteria are: Age ≥ 18 years; Patient treated with at least 3 months and up to 8 months of anticoagulation for an acute symptomatic PE diagnosed according the ESC and ACCP guidelines; Patients who have a PembQol score ≥ 10% and whose total scores for the subgroups Q1 (dyspnea) and Q4 (impact of daily life) are ≥ 10%.\n* Patients planned to be randomized\n* Abnormal conventional V\u002FQ scan at V1\n* Give consent to participate to the EOLE study\n\nExclusion Criteria:\n\n* Non inclusion criteria of the RAMBO trial:\n* Previsible inability to perform the effort test and\u002For PR\n* Presence of CTEPH according to international guidelines\n* Patients treated for acute PE with anticoagulants for more than 8 months\n* Active cancer or in remission for less than two years\n* Dyspnea post - COVID due to parenchymal injuries\n* Post-COVID hyperventilation syndrome without pulmonary vascular perfusion sequelae\n* Physical or psychological inability to undertake PR\n* Isolated or more distal segmental PE\n* Neuro-muscular disease with PR contraindication.\n* Cardiac insufficiency (unstable coronary artery disease)\n* Severe respiratory failure (long-term oxygen therapy, pulmonary hypertension)\n* Chronic dyspnea MMRC ≥ 2 before PE\n* Cardiac or respiratory rehabilitation in the previous year\n* Indication to urgent PR within 6 months at the time of inclusion\n* Life expectancy of less than 12 months\n* Inability to give consent\n* Patient under guardianship or curatorship\n* Patient deprived of liberty by an administrative or judicial decision\n* Patient has not social security affiliation or who don't beneficiary of such social security\n\nAfter initial PR work up, patients with following criteria cannot be included:\n\n* Incapacity to perform the effort test\n* Effort test stopped because of hemodynamic intolerance\n* Cardiac failure discovered after PR work up","99 Years",{"count":56,"type":22},32,"INTERVENTIONAL",[59],"NA","In patients with pulmonary embolism (PE), after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases.\n\nThe \"RAMBO\" trial is a French academic, multicenter, randomized (1:1 ratio), parallel arm, controlled, that aimed to assess the efficacy of pulmonary rehabilitation (PR) on the quality of life in patients with an acute symptomatic PE treated with anticoagulant therapy during at least 3 months and who present an impairment of quality of life and\u002For persistent dyspnea despite anticoagulant therapy.\n\nVentilation\u002FPerfusion (V\u002FQ) PET\u002FCT is a novel imaging modality for the assessment of regional lung function. The same carrier molecules as conventional V\u002FQ imaging are used, but they are labeled with 68Gallium, a ß+ isotope, instead of 99mTc, allowing acquisition of images with PET technology.\n\nThe EOLE study is an ancillary pilot study of the RAMBO trial, in which patients will benefit, in addition to the extensive work up scheduled as per study protocol, from a V\u002FQ PET\u002FCT scan before and after PR. The aim of the study is to assess the impact of PR on regional lung function with lung V\u002FQ PET\u002FCT imaging.",[62,26],"Pulmonary Embolism",[64,65,66],"Ventilation\u002Fperfusion PET\u002FCT","Galligas","68Ga-MAA","RECRUITING",{"date":69,"type":38},"2026-06-16",{"date":71,"type":38},"2023-06-22",{"date":73,"type":22},"2026-12-22",{"name":75,"class":76},"University Hospital, Brest","OTHER",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":57,"phases":87,"briefSummary":88,"conditions":89,"keywords":99,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100603978","early-exercise-based-rehabilitation-in-patients-hospitalized-for-acute-pulmonary-embolism-100603978","NCT07143539","Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism","Early Exercise-based Rehabilitation in High-risk Patients Hospitalized for Acute Pulmonary Embolism: a Pragmatic Multicenter Randomized Partially Blinded Superiority Trial","RehabPE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a high-probability ventilation-perfusion scintigraphy, and admission within the past 7 days\n3. Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension)\n2. Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment)\n3. Recently completed (i.e., \\\u003C6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication\n4. Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy)\n5. Contraindication to anticoagulation\n6. Life expectancy \\\u003C1 year based on the treating physician's clinical judgement\n7. Known pregnancy\n8. Inability to speak German or French\n9. Participation in another study that prohibits concurrent participation in RehabPE\n10. Unable to provide informed consent (e.g., due to dementia)\n11. Unwilling to provide informed consent\n12. Prior enrollment in this study",{"count":86,"type":22},160,[59],"Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects.\n\nThe study includes hospitalized patients with acute symptomatic PE who are at increased risk of impaired quality of life three months after diagnosis. After informed consent, patients are randomly assigned to one of two groups: one receives an early 6-8-week, center-based rehabilitation program; the other receives standard follow-up care without rehabilitation. The intervention group completes 16-18 outpatient sessions of endurance and strength training, along with two education sessions covering the condition, treatment, and symptom management.\n\nOver 180 days, changes in quality of life, physical exercise capacity, breathlessness, and psychological symptoms, and the time to return to work \u002F usual daily activities will be monitored and compared between groups.",[90,91,92,93,94,95,96,26,97,98],"Venous Thromboembolism (VTE)","Exercise Therapy","Quality of Life (QOL)","Anxiety Depression","Humans","Exercise Tolerance","Rehabilitation Exercise","Functional Status","Pulmonary Embolism (Diagnosis)",[100,101,102,103,104,105,106,30,107],"pulmonary embolism","deep vein thrombosis","excercise-based rehabilitation","post-PE syndrome","health-related quality of life","anxiety","depression","impact of early excercise-based rehabilitation","2026-06-11",{"date":110,"type":38},"2026-06-12",{"date":112,"type":38},"2025-12-17",{"date":114,"type":22},"2028-06",{"name":116,"class":76},"Insel Gruppe AG, University Hospital Bern",6,{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":18,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":130,"conditions":131,"keywords":135,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100642947","lung-and-heart-function-across-decades-of-life-in-health-100642947","NCT07641413","Lung and Heart Function Across Decades of Life in Health","Lung and Heart Function Across Decades of Life in Healthy Population","Inclusion Criteria:\n\n* Age 24-68\n* No respiratory complaints (defined as modified Medical Research Council score = 0)\n* No use of respiratory medications\n\nExclusion Criteria:\n\n* Non-English speaking\n* Pregnancy\n* BMI\\>35 Kg\u002Fm2\n* Tobacco smoking within prior year\n* Lifetime tobacco smoking of \\>5 pack-years\n* Current inhaled cannabis use (any modality) \\>2x weekly\n* Prior inhaled cannabis uses exceeding 2x weekly within the prior year\n* Illicit drug use (other than cannabis)\n* No prior or current major organ disease, including but not limited to:\n\n  * Neuromuscular weakness\n  * History of malignancy (other than non-melanoma skin cancer)-- HIV\u002FAIDS\n  * Autoimmune disease\n  * Solid-organ or hematopoietic stem cell transplant\n  * Cardiovascular disease (other than mild HTN; \\\u003C 140\u002F90; controlled on 2 or less medications)\n\n    * Poorly-controlled HTN (SBP\\>140 or DBP\\>90 or use of more than 2 anti-hypertensive medications)\n    * Any history of congestive heart failure (CHF, either HFpEF or HFrEF)\n    * Any history of arrythmia (including atrial fibrillation)",true,"24 Years","68 Years",{"count":129,"type":22},200,"The main objective of this study is to develop baseline \"normal\" reference values of both lung and heart function for healthy adults within the age range relevant to the United States Veteran population who served in the Southwest Asia theater of military operations.\n\nThis study will involve performing key components of the Department of Veterans Affairs the Airborne Hazards and Open Burn Pit Center of Excellence (AHOBPCE) and a VA network of Post-Deployment Cardiopulmonary Evaluation Network (PDCEN) Core Clinical Evaluation in asymptomatic unexposed healthy controls without known lung or heart disease to serve as a \"normal\" control comparator group for veterans evaluated by PDCEN.",[132,133,26,134],"Pollution Related Respiratory Disorder","Pollution; Exposure","Cardiopulmonary",[136,137,138,139,140,141],"Cardiopulmonary function","Pulmonary function testing","Forced oscillometry testing","Echocardiography","Cardiopulmonary exercise testing","Computed tomography imaging","2026-06-08",{"date":108,"type":38},{"date":145,"type":38},"2024-08-01",{"date":147,"type":22},"2030-12-31",{"name":149,"class":76},"University of California, San Francisco",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":57,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":46},"100642584","evaluation-of-the-benefits-of-hypnosis-in-improving-the-quality-of-life-of-patients-with-chronic-obstructive-pulmonary-disease-copd-suffering-from-persistent-dyspnea-100642584","NCT07637604","Evaluation of the Benefits of Hypnosis in Improving the Quality of Life of Patients With Chronic Obstructive Pulmonary Disease (COPD) Suffering From Persistent Dyspnea","Evaluation of the Benefits of Hypnosis in Improving the Quality of Life of Patients With Chronic Obstructive Pulmonary Disease (COPD) Suffering From Persistent Dyspnea: a Multicenter Randomized Controlled Trial","HYPNODYS","Inclusion Criteria:\n\n* Age \\>18 years\n* COPD (any etiology), referred by a pulmonologist and managed according to GOLD 2024 guidelines except for pulmonary rehabilitation that is not required\n* Outpatient follow-up\n* Residing in Paris or the inner suburbs for centers located within the city limits, or within a 30-minute drive for centers located outside the city limits of Paris.\n* Dyspnea rated as mMRC 3 or 4\n* Having signed an informed consent form\n\nExclusion Criteria:\n\n* Vulnerable individuals (under legal guardianship or curatorship) or deprived of liberty\n* Pregnant or breastfeeding women\n* Absolute or relative contraindication to the 6 minutes walk test, spirometry or body plethysmography\n* Current COPD exacerbation or exacerbation resolved less than one week ago\n* Psychosis or other psychiatric disorder likely to interfere with study participation\n* Profound hearing impairment\n* Cognitive impairment\n* Use of psychedelic substances (ex: LSD (Lysergic acid diethylamide), psilocybin, etc.)\n* Current participation in interventions that may be related to hypnosis: any kind of meditation, relaxation, sophrology, heart coherence training, yoga, Qi Gong, holotropic breathing, EMDR (Eye Movement Desensitization and Reprocessing) or any psychotherapies involving eye movements, as well as shamanic practices and brief psychotherapies or cognitive-behavioral therapies\n* Previous management of dyspnea using hypnosis\n* Ongoing pulmonary rehabilitation (physiotherapy outside a structured rehabilitation program initiated before study inclusion is not an exclusion criterion)\n* Inability to be reached by phone or teleconsultation\n* Lack of health insurance (French social security) coverage\n* Participation in another clinical trial\n* End of life",{"count":159,"type":22},154,[59],"Chronic Obstructive pulmonary Disease (COPD) is a common progressive disorder characterized by persistent airflow limitation. It is usually caused by exposure to tobacco smoke, toxic particles, or toxic gases. COPD is characterized by cough, sputum production, and dyspnea, which is the cardinal symptom and is included in the criteria for severity. Dyspnea is a major source of suffering and disability, especially when it persists at rest.\n\nDespite proper medical treatment, many patients continue to suffer from persistent dyspnea that significantly impairs their daily functioning and quality of life. Complementary approaches such as yoga and relaxation techniques are therefore recommended by some experts. Hypnosis is one of these practices. It has been shown to be effective in the management of both acute and chronic pain and it can abolish several types of experimentally induced dyspnea in healthy volunteers. In adults with COPD, a single hypnosis session has been shown to reduce anxiety immediately, though only temporarily. However, according to a recent retrospective study, a median of three hypnosis sessions increases the distance covered in the 6-minute walk test in COPD patients.\n\nThe investigators therefore hypothesize that several hypnosis sessions will improve the quality of life of adult outpatients with COPD who suffer from persistent dyspnea. The study plans to recruit 154 patients with severe dyspnea (mMRC(modified Medical Research Council Dyspnea Scale) 3 or 4). They will be randomly assigned to either the experimental group or the control group. Patients in the experimental group will participate in 5 sessions of medical hypnosis spaced 7 ± 2 days apart. The first hypnosis session will take place at the end of the enrollment visit. The final session will be held via teleconsultation. Four standardized telephone calls, spaced 7 ± 2 days apart, will replace the hypnosis sessions in the control group. The primary outcome of the study will be the evolution of quality of life, assessed 6 weeks after the start of the study as compared to baseline. Secondary outcomes will focus on changes in exercise capacity, dyspnea, anxiety, depression, dyspnea-related catastrophizing, self-efficacy, and pleasure in life.",[163,26],"Chronic Obstructive Pulmonary Disease (COPD)",[163,165,166],"Dyspnea,","Hypnosis","2026-06-05",{"date":169,"type":38},"2026-06-10",{"date":171,"type":22},"2026-09-01",{"date":173,"type":22},"2029-12-15",{"name":175,"class":76},"Assistance Publique - Hôpitaux de Paris",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":57,"phases":186,"briefSummary":187,"conditions":188,"keywords":193,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":46},"100606268","hypnosis-on-breathlessness-mastery-in-patients-with-persistent-dyspnea-100606268","NCT07173348","Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea","Effectiveness of Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea: a Randomised Controlled Trial","HYPNEA","Inclusion Criteria:\n\n* Patients aged ≥ 18 years and\n* Primary diagnosis of metastatic cancer, COPD stage at least B or E, ILD, or CHF and\n* Dyspnea stage NYHA ≥ II or mMRC ≥ 2\n\nExclusion Criteria:\n\n* Have had hypnosis treatment in the last 12 months\n* Have an estimated life expectancy of less than 6 months\n* Have participated in pulmonary rehabilitation in the last 6 months\n* Have been hospitalised in the last month (30 days)\n* Are unable to come to the hospital for 3 outpatient consultations (1 every two weeks)\n* Have a condition that would interfere with their ability to respond to the questionnaires (i.e. cognitive impairment, hearing impairment, etc.)\n* Are not eligible for a hypnosis session due to a psychiatric disorder",{"count":185,"type":22},82,[59],"Persistent dyspnea is a debilitating symptom, that is common and difficult to treat. This symptom is found in many different diseases including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), chronic heart failure (CHF), and metastatic cancer. Dyspnea is associated with many other symptoms, including anxiety, depression, and fatigue and is responsible for a significant reduction in quality of life. To date, only opiates are recommended for the pharmacological treatment of persistent dyspnea.\n\nThe effectiveness of hypnosis is well known in the treatment of anxiety and delivered to patients suffering from chronic dyspnea for this reason. One randomised controlled study has shown that a single 20-minute mindfulness sessions could significantly reduce general symptom burden and have a significant impact on anxiety and depression in palliative care patients. Furthermore, the intervention had no negative side effects.\n\nOur aim is to evaluate the effectiveness of three hypnosis sessions on breathlessness mastery in patients with persistent dyspnea, using as a primary outcome the mastery domain of a validated tool, the Chronic Respiratory Questionnaire (CRQ).",[189,190,191,192,26],"Cancer (With or Without Metastasis)","Interstitial Lung Disease (ILD)","Chronic Heart Failure (CHF)","COPD",[166,194,195,196,197,198,199],"Persistant dyspnea","Cancer with metastasis","Chronic Obstructive Pulmonary Disease","Interstitial Lung Disease","Chronic Heart Failure","Palliative Care",{"date":142,"type":38},{"date":202,"type":38},"2026-04-01",{"date":204,"type":22},"2028-04-01",{"name":206,"class":76},"University Hospital, Geneva",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":46},"100558686","cardiopulmonary-exercise-testing-and-oscillometry-for-the-evaluation-of-dyspnea-100558686","NCT06554353","Cardiopulmonary Exercise Testing and Oscillometry for the Evaluation of Dyspnea","COED","Inclusion Criteria:\n\n* Willingness to perform breathing test\n* Must be able to speak and understand English\n* Referred for Cardiopulmonary Exercise Testing\n\nExclusion Criteria:\n\n* Unable to provide consent or perform oscillometry test",{"count":215,"type":22},50,"This study will determine if airway resistance to airflow and pressure, measured by Oscillometry, is associated with abnormal findings on Cardiopulmonary Exercise Testing in subjects who are experiencing shortness of breath.",[218,219,26,220],"Breathing, Mouth","Lung Function Decreased","Shortness of Breath","2026-06-01",{"date":223,"type":38},"2026-06-03",{"date":225,"type":38},"2024-10-29",{"date":227,"type":22},"2026-11-30",{"name":229,"class":76},"University of Rochester",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":57,"phases":240,"briefSummary":241,"conditions":242,"keywords":246,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":264},"100640437","effect-of-different-breathing-techniques-on-dyspnea-and-cardiopulmonary-parameters-among-patients-after-open-heart-surgery-100640437","NCT07591987","Effect of Different Breathing Techniques on Dyspnea and Cardiopulmonary Parameters Among Patients After Open Heart Surgery","Effect of Segmental Breathing Versus Active Cycle Breathing Techniques on Dyspnea and Cardiopulmonary Parameters Among Patients After Open Heart Surgery: Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age 18-75 years.\n* Scheduled for elective open-heart surgery.\n* Can understand instructions and perform Segmental breathing and Active cycle breathing techniques.\n* Stable preoperative hemodynamic condition.\n\nExclusion Criteria:\n\n* Emergency cardiac surgeries.\n* Patients with pre-existing severe pulmonary disease (e.g., COPD, asthma, restrictive lung disease, Atelectasis, and Tuberculosis).\n* Neurological disorders affecting breathing effort.\n* Patients with rib fractures, recent thoracic trauma, or contraindications for coughing maneuvers.\n* Inability to provide informed consent (cognitive impairment, language barrier).","75 Years",{"count":239,"type":22},99,[59],"Open heart surgery is often associated with postoperative pulmonary complications, reduced lung expansion, dyspnea, and impaired cardiopulmonary function. Breathing exercises are commonly used after surgery to improve lung ventilation, enhance oxygenation, and support respiratory recovery. However, limited evidence is available comparing the effectiveness of segmental breathing exercises and active cycle breathing technique (ACBT) in patients after open heart surgery.\n\nThis randomized controlled trial will compare the effects of segmental breathing exercises and ACBT on dyspnea and cardiopulmonary parameters in adults undergoing open heart surgery. Participants will be randomly assigned to either the segmental breathing exercise group, the ACBT group, or the standard care group during the postoperative period following extubation.\n\nCardiopulmonary parameters, including oxygen saturation, respiratory rate, heart rate, and blood pressure, as well as dyspnea severity and postoperative pulmonary complications, will be assessed before and after the interventions.\n\nThe findings of this study may help identify the most effective breathing exercise technique for improving respiratory outcomes, reducing postoperative pulmonary complications, and supporting evidence-based postoperative rehabilitation after cardiac surgery.",[26,243,244,245],"Cardiopulmonary Dysfunction","Postoperative Respiratory Dysfunction","Coronary Artery Disease",[247,248,249,250,251,252,253,26,254],"Open Heart Surgery","Cardiac Surgery","Breathing Exercises","Segmental Breathing Exercises","Active Cycle Breathing Technique","Postoperative Patients","Adult Patients","Cardiopulmonary Parameters","2026-05-14",{"date":257,"type":38},"2026-05-18",{"date":259,"type":38},"2026-01-02",{"date":261,"type":22},"2026-10-10",{"name":263,"class":76},"University of Baghdad",3,{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":57,"phases":277,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":299},"100511316","phase-2-breathe-easier-with-tadalafil-therapy-for-dyspnea-in-copd-ph-100511316","NCT05937854","Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH","Effect of PDE5 Inhibitor on Respiratory Symptoms in COPD Complicated by Pulmonary Hypertension","BETTER COPD-PH","Inclusion Criteria:\n\n1. Outpatients with COPD, defined as airflow limitation with post-bronchodilator obstruction on baseline visit spirometry, identified by FEV1\u002FFVC \\\u003C 70% or \\\u003C the lower limit of normal (5th percentile of a normal population based on Global Lung Function Initiative reference equations), OR any emphysema on chest CT noted in a clinical radiology report confirmed by study investigator review.\n2. Eligible subjects must have PH documented as follows:\n\n   1. Main Pulmonary Artery\u002FAscending Aorta (PA\u002FA) diameter \\> 0.90 on clinically available CT scans within 12 months OR\n   2. Main Pulmonary Artery diameter \\> 30.8mm on clinically available CT scans within 12 months OR\n   3. outpatient echocardiography done within 6 months of enrollment demonstrating PA sys \\> 34 mmHg OR\n   4. Mean Pulmonary Artery Pressure \\> 20 on Right Heart Catheterization done within 6 months of enrollment and when Veteran is clinically stable.\n3. Eligible subjects must be dyspneic, as quantitated by a score of at least 20 on the baseline UCSD Shortness of Breath Questionnaire, assessed at the time of the baseline visit.\n4. Treatment with at least one long-acting bronchodilator for at least 4 weeks, assessed at the time of the baseline visit by chart review and patient interview.\n5. Age 35-89 Years\n6. Women of childbearing potential must meet one of the following criteria for the previous three months AND must have a negative pregnancy test on the day of testing. If more than 36 hours since the participant's last pregnancy test, they will be tested again at the study visit.\n\n   1. have been using a contraceptive measure (an intrauterine device (IUD), a contraceptive implant, oral contraceptives, barrier methods, or abstinence)\n   2. have a male partner with a vasectomy\n   3. have a tubal ligation procedure or a medical diagnosis (such as infertility) or therapies\u002Fprocedures that precludes pregnancy (such as cancer treatments or endometrial ablation)\n   4. are in a same-sex relationship\n   5. have a male partner not capable of fathering children because of congenital anomalies, other surgery, or medical treatment\n7. Women who are not considered to be of childbearing potential who have been surgically sterilized (for example: removal of ovaries or fallopian tubes, or hysterectomy) or are post-menopausal (no menstrual period for more than 6 months).\n\nExclusion Criteria:\n\n1. Diagnosis of PH in the following subgroups of the updated WHO Clinical Classification:\n\n   1. Group 1 (Idiopathic, heritable, drug- or toxin-induced, Pulmonary Arterial Hypertension associated with connective tissue disease, congenital heart disease)\n   2. Group 2 (left atrial hypertension)\n   3. Group 3 PH not attributable to COPD\n   4. Group 4 (chronic thromboembolic PH) or other forms of PH not associated with primary lung disease.\n2. Systemic hypotension in the ambulatory setting (at least 3 reproducible measurements of systolic BP \\\u003C89 mmHg, recorded by a health care provider over 1 week).\n3. Moderate or severe hepatic impairment (Child-Pugh B and C).\n4. Severe renal insufficiency (GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2)\n5. Echocardiography within 6 months showing greater than moderate aortic stenosis (aortic valve area \\\u003C1.0 cm2), greater than moderate mitral regurgitation, or diastolic dysfunction (Any two of the following: Average E\u002Fe' \\>14, Septal e' velocity \\\u003C 7 or lateral e' velocity \\\u003C10, LA volume index \\> 34 ml\u002Fm2). LVEF \\\u003C 50%. Any aortic or mitral valve replacement.\n6. Any acute or chronic impairment (other than dyspnea) that limits ability to comply with the study requirements.\n7. Current unstable angina, myocardial infarction or stroke within 6 months.\n8. Requirement for nitrate therapy for any clinical indication.\n9. Active prescription for a PDE-5 inhibitor or other pulmonary vasodilator other than oxygen as a PH treatment.\n10. History of the following retinal disorders: retinitis pigmentosa, non-arteritic anterior ischemic optic neuropathy, or crowded optic disc noted on ophthalmology examinations recorded in CPRS.\n11. Contraindications: PDE-5i allergy, penile anatomical deformations, sickle cell anemia, multiple myeloma, leukemia, bleeding disorders, active peptic ulcer disease, retinitis pigmentosa or other retinal disorders listed above. In accordance with 38 USC 7332, this information will be kept confidential and will not be disclosed in presentations, publications, or any other dissemination of the study results, or to anyone outside of the IRB-approved study team.\n12. Use of any of the following: rifampin, systemic anti-fungal azole agents, protease inhibitors, phenobarbital, dilantin.\n13. Pregnant, possibly pregnant by report, or if breastfeeding. If found to be pregnant at the study visit, the study visit will not be conducted.\n14. Pulmonary veno-occlusive disease\n15. Hypoxia (reproducible ambulatory SaO2 \\\u003C 90% on supplemental oxygen at rest recorded by a health care provider over 1 week).\n16. Diagnosis of Obstructive Sleep Apnea without a prescription for treatment.\n17. Newly prescribed (less than 4 weeks duration) bronchodilator or diuretic therapy or new enrollment in pulmonary rehabilitation at the time of Baseline.\n18. Students, VA employees, persons with impaired decision making, illiterate and non-English speakers, and terminally ill patients.\n19. COPD or CHF exacerbation within the past 4 weeks.\n20. On-going therapy with doxazosin.\n\nWomen of childbearing potential must have a documented negative pregnancy test and must be using adequate contraception during the study and for 9 months afterward. Monthly pregnancy tests will be done, and compliance with contraception use will be documented at the telephone and clinic visits. Should a female become pregnant at any time during the study, the study medication will be discontinued.\n\nDoxazosin use will be defined as current active prescription and usage of Doxazosin or planned trial (pending prescription) of Doxazosin for treatment of benign prostatic hypertrophy, systemic hypertension, or other indication. A list of alpha-1 antagonists (ex. prazosin, doxazosin, tamulosin, terazosin, etc.) will be included in the patient study medication handout to prompt the patient to avoid any new usage of these drugs during the trial period. On-going therapy with doxazosin is an exclusion criterion due to greater risk of hypotension.","35 Years","89 Years",{"count":276,"type":22},126,[278],"PHASE2","The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function. Veterans who enroll in the trial will be allocated by chance to either active tadalafil or an inactive identical capsule (placebo). Neither the Veteran nor the investigator will know whether the Veteran is taking tadalafil or placebo. Veterans will be followed closely in clinic or by telephone at 1, 2, 3, 4, 5, and 6 months, with attention to side effects and safety. At 1,3, and 6 months the investigators will repeat the questionnaires and testing of blood pressures in the lung and lung function. The investigators anticipate that the results of this study will determine whether tadalafil improves shortness of breath when added to usual medications for COPD.",[196,281,26],"Pulmonary Hypertension",[192,283,284,285,286,287,288,30,289],"cigarette smoke","lung","echocardiography","chest CT","physical activity","spirometry","clinically important deterioration",{"date":291,"type":38},"2026-05-15",{"date":293,"type":38},"2024-04-01",{"date":295,"type":22},"2029-03-01",{"name":297,"class":298},"VA Office of Research and Development","FED",5,{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":320,"locationsCount":46},"100582695","evaluating-dyspnea-in-autoimmune-myasthenia-gravis-why-am-i-short-of-breath-100582695","NCT06866652","Evaluating Dyspnea in Autoimmune Myasthenia Gravis \"Why am I Short of Breath?\"","MyaRESP","Inclusion Criteria:\n\n* Age ≥18\n* Confirmed diagnosis of autoimmune MG\n* Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score\n* Signed consent form\n* Affiliated to or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Known Pregnancy\n* Known respiratory disorder (other than MG)\n* Recent (within past 4 weeks) respiratory infection\n* Current MG crisis or exacerbation (necessitating increase in MG medication \\&\u002For hospital admission)\n* No dyspnea - score 0 or 3 on the respiration item on the MG- activities of daily living score\n* Severe cognitive impairment\u002Fguardianship",{"count":215,"type":22},"Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Identifying the cause(s) of dyspnea in MG may assist in finding therapeutic strategies, reducing discomfort, improving QoL and potentially limiting respiratory deterioration and incidence of MG crisis.",[310,26],"Myasthenia Gravis",[30,312,313],"breathlessness","respiratory","2026-05-04",{"date":316,"type":38},"2026-05-08",{"date":318,"type":38},"2026-04-08",{"date":114,"type":22},{"name":321,"class":76},"Institut de Myologie, France",{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":57,"phases":333,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":4},"100634669","respiratory-physiotherapy-and-pmr-after-cardiac-surgery-100634669","NCT07542691","Respiratory Physiotherapy and PMR After Cardiac Surgery","Effect of Respiratory Physiotherapy and Progressive Muscle Relaxation Exercises on Dyspnea, Anxiety, Hemodynamic Status and Delirium Symptoms After Cardiac Surgery: A Randomized Controlled Trial","RESP-PMR","Inclusion Criteria:\n\n* Patients aged 18-80 years who have undergone cardiac surgery\n* Hemodynamically stable patients\n* Patients able to cooperate and follow instructions\n* Patients with postoperative dyspnea\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or inability to cooperate\n* Patients with neurological or psychiatric disorders affecting participation\n* Patients requiring mechanical ventilation for prolonged periods\n* Patients with unstable hemodynamic status\n* Patients with contraindications to respiratory physiotherapy or exercise\n* Patients who refuse to participate","80 Years",{"count":332,"type":22},116,[59],"This study aims to evaluate the effects of respiratory physiotherapy combined with progressive muscle relaxation exercises on dyspnea, anxiety, hemodynamic status, and delirium symptoms in patients after cardiac surgery. This randomized controlled trial will include 116 patients who will be randomly assigned to an intervention group or a control group. The intervention group will receive respiratory physiotherapy and progressive muscle relaxation exercises in addition to routine postoperative care for 30 minutes per day over three consecutive days, while the control group will receive routine care only. Outcome measures will include dyspnea assessed by the Modified Borg Scale, anxiety assessed by the State-Trait Anxiety Inventory, hemodynamic parameters obtained from vital signs, and delirium symptoms assessed using the Nursing Delirium Screening Scale. It is hypothesized that the combined intervention will reduce dyspnea and anxiety levels, improve hemodynamic stability, and decrease delirium symptoms. The findings are expected to contribute to improved postoperative recovery and reduced complication risks following cardiac surgery.",[248,26,336,337],"Anxiety","Delirium",[339,340,341,342,343,344],"Respiratory Physiotherapy","Progressive Muscle Relaxation","Cardiac Rehabilitation","Postoperative Care","Intensive Care Unit","Hemodynamic Parameters","2026-04-17",{"date":347,"type":38},"2026-04-21",{"date":349,"type":22},"2026-05",{"date":351,"type":22},"2026-06",{"name":353,"class":76},"Istanbul Aydın University",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":362,"minAge":19,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":57,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":46},"100622655","inspiratory-muscle-training-for-breast-cancer-patients-on-chemotherapy-100622655","NCT07386444","Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy","Effects of Inspiratory Muscle Training Among Breast Cancer Patients Undergoing Active Treatment (IMACT)","IMACT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Within 3 weeks of starting chemotherapy for an early-stage breast cancer diagnosis\n* Able to exercise independently without needing support\n* Ability to read, speak, understand English\n\nExclusion Criteria:\n\n* Metastatic breast cancer\n* Unwilling or unable to follow protocol requirements\n* Any significant health condition which in the investigator's opinion increases the risks of participation or makes the participant unsuitable for the study","FEMALE",{"count":364,"type":22},58,[59],"This clinical trial studies whether breathing exercises for the muscles that help with breathing air in, inspiratory muscle training (IMT), works to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage breast cancer (BC). Cancer and\u002For treatments for BC can directly result in muscle wasting that involves breathing muscles, skeletal muscles or heart muscles. Pain, weakness, shortness of breath, and side effects of cancer treatment may lead to lower physical activity levels. IMT involves breathing exercises using a small hand-held device. The device makes it a little harder to breathe in, which may help strengthen breathing muscles. IMT may be an effective way to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage BC.",[368,26],"Early Stage Breast Carcinoma",{"date":370,"type":38},"2026-04-06",{"date":372,"type":38},"2026-02-16",{"date":374,"type":22},"2026-12-31",{"name":376,"class":76},"Ohio State University Comprehensive Cancer Center",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":57,"phases":385,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":46},"100541959","phase-2-structured-personalized-oxygen-and-supportive-therapies-for-dyspnea-in-oncology-100541959","NCT06336642","Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology","Inclusion Criteria:\n\n* Diagnosis of cancer\n* Age 18 or older.\n* Admitted to a medical floor.\n* Dyspnea intensity at rest of at least 4 on a 0-10-point NRS (where 0 = none, 10 = worst).\n* Speak English or Spanish.\n\nExclusion Criteria:\n\n* Hemodynamic instability requiring active Merit Team or ICU team involvement.\n* Delirium as per clinical team's assessment in the Electronic Health Record (EHR).\n* Severe hypoxemia (SpO2 \\\u003C 90% despite supplemental oxygen of up to 6 L\u002Fmin).\n* Continuous positive airway pressure (CPAP) use for obstructive sleep apnea, actively using \\>10 hours a day.\n* Respiratory failure necessitating mechanical ventilation (i.e., HFNC or NIV), and planned thoracentesis within 72 hours of enrollment.\n* Patients with known pregnancy.",{"count":384,"type":22},150,[278,386],"PHASE3","To learn about the effect of Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON) treatment on the severity of shortness of breath in patients with cancer.",[26],"2026-03-09",{"date":391,"type":38},"2026-03-10",{"date":393,"type":38},"2024-06-11",{"date":395,"type":22},"2032-03-31",{"name":397,"class":76},"M.D. Anderson Cancer Center",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":125,"sex":18,"minAge":404,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":57,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":46},"100556419","the-increase-of-lung-capacity-using-the-lung-master-pulmonary-exerciser-100556419","NCT06524856","The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)","Inclusion Criteria:\n\n* able to complete the at home portion of the study daily\n* fall within the age ranges: 19-35 and above 65 years old\n\nExclusion Criteria:\n\n* any respiratory or chronic conditions","19 Years",{"count":406,"type":22},20,[59],"Investigators are studying how a device called The Lung Master device can help people breathe better. The investigational device increases the amount of air our lungs can hold, which is important for overall lung health. The Lung Master is not approved by the FDA.\n\nThe study has two visits approximately one month apart. In the first visit participants will take a spirometry test, particularly forced vital capacity (FVC), to measure volume change in the lungs. Participants will take the investigational device home to use daily, either in the morning or evening. Use will be recorded in a diary. After one month, participants will return for another spirometry test. Each study visit will take about one to two hours to complete.",[26,196,410],"Asthma","2026-03-06",{"date":413,"type":38},"2026-03-11",{"date":415,"type":38},"2024-10-01",{"date":417,"type":22},"2027-03",{"name":419,"class":76},"University of Nebraska",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":46},"100558874","proof-of-concept-study-on-dyspnea-analysis-via-gapco2-100558874","NCT06556797","Proof-of-concept Study on Dyspnea Analysis Via GapCO2","How to Differentiate Congestive and Non-congestive Dyspnea in the Emergency Department? Proof-of-concept Study on Microperfusion Analysis Via GapCO2","MicroDys","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient presenting with acute dyspnea defined by a sensation of respiratory discomfort with at least one of the following criteria: RR ≥ 22 and\u002For SpO2 \\\u003C 95%\n* Arterial blood gas sampling performed as part of care\n* Inclusion less than 1 hour after arrival time to the emergency department\n* Non-opposition to participation in the study\n\nExclusion Criteria:\n\n* Temperature greater than or equal to 37.5°C\n* Patient who has already received a diuretic or vasodilator treatment in the emergency department or by a prehospital medical team\n* Systolic blood pressure less than or equal to 100 mmHg and\u002For signs of peripheral hypoperfusion\n* Inability to express refusal to participate in the study",{"count":429,"type":22},45,"Patients presenting to the emergency department with acute dyspnea undergo arterial blood gas measurement and monitoring of transcutaneous capnography using the TCM5 monitor. The aim of this study is to determine whether GapCO2, the difference between transcutaneous and arterial pCO2 (PaCO2 - PtcCO2), is correlated with the congestive or non-congestive origin of dyspnea.",[432,26],"Acute Dyspnea",[434,435,26,436,437,438],"Acute dyspnea","Emergency department","Congestion","Proof-of-concept study","GapCO2","2026-02-06",{"date":441,"type":38},"2026-02-10",{"date":443,"type":38},"2025-01-26",{"date":445,"type":22},"2026-04-26",{"name":175,"class":76},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":125,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":57,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":46},"100519060","phase-2-129xe-mri-cardiopulmonary-100519060","NCT06038630","129Xe MRI Cardiopulmonary","129Xe Gas Exchange MRI to Visualize Cardiopulmonary Function","Inclusion Criteria for Healthy Volunteers:\n\n(Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial)\n\n1. Outpatients of either gender, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol (Consent must be given before any study procedures are performed.)\n3. Subject has no diagnosed pulmonary conditions\n4. Subject has not smoked in the previous 5 years\n5. Smoking history, if any, is less than or equal to 5 pack-years\n6. No history of using other inhaled products more than 1\u002Fweek for \\> 1 year\n\nInclusion Criteria for Transfusion and Phlebotomy Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following:\n\n1. Patients who are scheduled to receive a red cell transfusion for anemia.\n2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia\n3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above)\n\nInclusion Criteria for Oxygen Administration Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (ILD, Dyspnea, CTEPH, or Healthy):\n\n1. Interstitial Lung Disease or Dyspnea\n\n   * Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\n   OR\n3. Healthy Volunteer (criteria noted above)\n\nInclusion Criteria for Acute or Chronic Pulmonary Embolism Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (Acute or Chronic)\n\n1. Acute Pulmonary Embolism\n\n   * Patients presenting with acute PE 24-48hrs post-admission\n   * Willing to return after 3-6 months of anti-coagulation therapy\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\nExclusion Criteria for All subjects:\n\nSubjects presenting with any of the following will not be included in the trial:\n\n1. MRI is contraindicated based on responses to MRI screening questionnaire\n2. Subject is pregnant or lactating\n3. Resting O2 saturation \\\u003C90% with maximum supplemental O2 delivered by nasal canula\n4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI\n5. Subject has history of any known ventricular cardiac arrhythmia\n6. Subject has history of cardiac arrest within the last year\n7. Subject does not fit into 129Xe vest coil used for MRI\n8. Subject cannot hold his\u002Fher breath for 10 seconds\n9. Subject deemed unlikely to be able to comply with instructions during imaging\n10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements",{"count":455,"type":22},125,[278],"The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.",[197,459,460,461,462,26],"Chronic Thromboembolic Pulmonary Hypertension","Acute Pulmonary Embolism","Anemia","Polycythemia","2026-02-02",{"date":465,"type":38},"2026-02-04",{"date":467,"type":38},"2024-01-12",{"date":469,"type":22},"2028-06-30",{"name":471,"class":76},"Bastiaan Driehuys",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":482,"conditions":483,"keywords":486,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":46},"100508636","diaphragmatic-function-as-a-biomarker-100508636","NCT05903001","Diaphragmatic Function as a Biomarker","Diaphragmatic Function as a Biomarker in Patients With Respiratory Diseases","DFUNBIO","Inclusion Criteria:\n\n* patient has one of the following lung diseases: COPD, bronchial asthma, pulmonary fibrosis, pulmonary hypertension\n* is 18 years or older\n* is mentally and physically able to understand the study and to follow instructions\n* are legally competent\n* signed declaration of consent\n\nExclusion Criteria:\n\n* BMI \\> 35\n* current or treatments or diseases in the past which could influence the evaluation of the study\n* Expected lack of willingness to actively participate in study-related measures\n* alcohol or drug abuse\n* disc herniation\u002Fprolapse\n* epilepsy\n* wheelchair bound\n* in custody due to an official or court order\n* in a dependent relationship or employment relationship with investigating physician or one of their deputy\n* emergency inpatient hospital stay within 4 weeks before study-specific examinations",{"count":481,"type":22},800,"Dyspnea is among the most common symptoms in patients with respiratory diseases such as Asthma, chronic obstructive pulmonary disease (COPD), Fibrosis, and Pulmonary Hypertension. However, the pathophysiology and underlying mechanisms of dyspnea in patients with respiratory diseases are still poorly understood. Diaphragm dysfunction might be highly prevalent in patients with dyspnea and respiratory diseases. The association of diaphragm function and potential prognostic significance in patients with respiratory diseases has not yet been investigated.",[484,192,485,281,410,26],"Dyspnea; Asthmatic","Fibrosis",[30,192,487,488,489,490],"asthma","fibrosis","pulmonary hypertension","pneumology","2026-01-26",{"date":493,"type":38},"2026-01-28",{"date":495,"type":38},"2023-07-01",{"date":497,"type":22},"2026-12-30",{"name":499,"class":76},"RWTH Aachen University",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":46},"100617927","acute-dyspnea-in-the-emergency-department-diagnostic-value-of-point-of-care-ultrasound-100617927","NCT07324980","Acute DYSPnea in the Emergency Department: Diagnostic Value of Point-of-care UltraSound","Acute Dyspnea in the Emergency Department: Diagnostic Evaluation of Inferior Vena Cava Ultrasound Integrated With Multimodal Point-of-Care Ultrasound and Clinical Data","DYSP-ED-US","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Presentation to the emergency department with acute dyspnea and acute respiratory failure, defined by at least one of the following:\n\n  * PaO₂ \\\u003C 60 mmHg on room air, or\n  * Oxygen saturation (SpO₂) \\\u003C 90% on room air, or\n  * PaO₂\u002FFiO₂ ratio \\\u003C 300.\n* Ability to provide written informed consent or eligibility for deferred consent according to local regulations.\n* Undergoing standard diagnostic evaluation including laboratory tests and chest imaging as part of routine clinical care.\n\nExclusion Criteria:\n\n* Refusal to provide informed consent (or consent by legal representative when applicable).\n* Inadequate ultrasound window or technically insufficient ultrasound assessment.\n* Acute respiratory failure secondary to chest trauma.\n* Cardiac arrest at presentation or during emergency department stabilization.\n* Requirement for invasive mechanical ventilation during initial stabilization in the emergency department.",{"count":129,"type":22},"Acute dyspnea is a common reason for emergency department (ED) admission and is frequently caused by acute heart failure with pulmonary edema. Rapid differentiation between cardiogenic and non-cardiogenic causes of dyspnea is essential to guide early treatment and risk stratification. However, no single gold standard exists for the assessment of venous congestion in the acute setting.\n\nThis prospective observational study aims to evaluate the diagnostic accuracy of respiratory variation in inferior vena cava (IVC) diameter measured by point-of-care ultrasound (POCUS) in identifying acute pulmonary edema in patients presenting to the ED with acute respiratory failure. In addition, the study investigates whether integration of IVC ultrasound with lung ultrasound, bedside cardiac ultrasound, and selected clinical and laboratory variables - such as hemoglobin and plasma protein changes - improves diagnostic performance and prognostic stratification.",[511,512,26],"Hydrostatic Pulmonary Edema","Acute Respiratory Failure","2025-12-23",{"date":515,"type":38},"2026-01-08",{"date":517,"type":38},"2025-11-01",{"date":519,"type":22},"2028-11",{"name":521,"class":76},"Università degli Studi del Piemonte Orientale Amedeo Avogadro",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":125,"sex":18,"minAge":19,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":57,"phases":533,"briefSummary":534,"conditions":535,"keywords":538,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":551},"100613612","effect-of-fan-application-in-preventing-ticagrelor-associated-dyspnea-100613612","NCT07268859","Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea","Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome.","ACS","Inclusion Criteria:\n\n* Between the ages of 18 and 65,\n* No severe hearing and vision problems,\n* Can speak and understand Turkish,\n* Easy to communicate with,\n* First-time sufferer of acute coronary syndrome (ACS) for the first time,\n* Decided to start ticagrelor therapy,\n* Able to adapt to treatment,\n* Individuals who volunteered to participate in the research.\n\nExclusion Criteria:\n\n* Having any problem that prevents you from communicating cognitively, emotionally and verbally,\n* Obstructive sleep abnormalities,\n* Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.),\n* With metabolic abnormalities,\n* Intubated after the procedure,\n* Previously treated with ticagrelor,\n* Individuals who did not volunteer to participate in the study. Losses to follow up\n* Individuals who wish to leave the study voluntarily.\n* Saturation value below 95%,\n* The one with the arrest,\n* Who will not be able to fulfill the requirements of the work,\n* Individuals with life-threatening conditions","65 Years",{"count":532,"type":22},110,[59],"This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.",[536,537,26],"Acute Coronary Syndromes","Ticagrelor",[539,537,540,26,541],"Nursing","Hand fan therapy","Non-pharmacological intervention","2025-12-04",{"date":544,"type":38},"2025-12-08",{"date":546,"type":38},"2025-03-15",{"date":548,"type":22},"2026-01-30",{"name":550,"class":76},"Acibadem University",2,{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":530,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":57,"phases":562,"briefSummary":563,"conditions":564,"keywords":566,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":46},"100578183","lung-and-cardiac-ultrasound-for-respiratory-distress-in-elderly-100578183","NCT06807983","LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly","Impact of a Management Strategy for Acute Dyspnea in Elderly Subjects Based on the Use of Lung and Cardiac Ultrasonography","LUCREED","Inclusion Criteria:\n\nEligible patients will be aged over 65 years, affiliated with the French social security system, and presenting to the ED with acute dyspnea (onset \\\u003C14 days) accompanied by severity signs before or at triage (respiratory rate ≥22 and SpO2 \\\u003C92% on room air). The enrolling emergency physician (EP) must be the patient's treating physician and must be trained in LuCUS. Written informed consent from the patient or their legal representative is required for inclusion\n\nExclusion Criteria:\n\ndyspnea secondary to thoracic trauma, dyspnea clearly related to COVID-19, known pulmonary fibrosis or lung cancer, prior administration of specific treatment for dyspnea before inclusion, immediate need for endotracheal intubation, patients identified as being at end-of-life, and individuals under legal guardianship or deprived of liberty.",{"count":561,"type":22},504,[59],"Prospective trial to evaluate the impact on the initial therapeutic inadequacy of a management strategy for acute dyspnea in the elderly based on the use of lung and cardiac ultrasonography.",[26,565],"Respiratory Distress Syndrome",[567,568,569,26],"Elderly","Point-of-Care Ultrasound","Respiratory Distress Syndrom","2025-11-26",{"date":542,"type":38},{"date":573,"type":38},"2025-11-04",{"date":575,"type":22},"2027-05-01",{"name":577,"class":76},"University Hospital, Toulouse",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":125,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":57,"phases":588,"briefSummary":589,"conditions":590,"keywords":591,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":46},"100499574","menthol-for-dyspnea-relief-in-health-and-copd-100499574","NCT05785026","Menthol for Dyspnea Relief in Health and COPD","Effectiveness and Mechanisms of Menthol Inhalation for the Relief of Dyspnea in Health and COPD","MENTHODYSC","Inclusion Criteria:\n\n* Age: 18 years of age or older\n* Able to speak, read, and write Dutch or English\n* Normal pulmonary function: forced expiratory volume in 1 second (FEV1) to forced vital capacity ratio\\>0.70; FEV1≥80%predicted (WP1 and 2 only)\n* Non-smoker or former smokers (smoke-free ≥12 months prior to enrolment) (WP1 and 2 only)\n* Clinically stable COPD (based on clinical judgment of the study physician that have not had exacerbations requiring escalation of medical therapy (i.e., short course of oral corticosteroids or antibiotics) within the preceding 14 days (WP3 and 4 only)\n\nExclusion Criteria:\n\n* Contraindication to exercise testing (e.g., significant cardiovascular, musculoskeletal, neurological disease; see Table 4 from ERS\u002FATS consensus statement)\n* Significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could influence dyspnea and\u002For impair exercise capacity (with the exception of COPD in WP3 and 4)\n* Body mass index \\\u003C18.5 or \\>35 kg\u002Fm2\n* An ulcer or tumor in the esophagus, a nasal septum deviation, or recent nasopharyngeal surgery\n* Severe facial trauma including cribriform plate disruption (bone separating brain from nasal cavity)\n* Allergies to latex and sensitivities to local anesthetics\n* Inability to give informed consent, including those with significant cognitive impairment\n* Alcohol consumption within 12 hours of study visit\n* Current smoker\\*\n* History of early menopause (age \\\u003C45 years)\n* Pregnancy or desire to become pregnant while in trial",{"count":587,"type":22},120,[59],"Menthol inhalation (MI) is a novel and promising treatment option for acute relief of dyspnea, however, the underlying ventilatory and\u002For neural related mechanisms for this relief in symptoms remain unknown. The overall aim of this research project is to systematically examine the mechanisms of dyspnea relief from MI in healthy individuals and those with COPD.",[26,196],[592],"Menthol","2025-11-17",{"date":595,"type":38},"2025-11-19",{"date":597,"type":38},"2023-01-01",{"date":599,"type":22},"2028-10-31",{"name":601,"class":76},"KU Leuven",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":57,"phases":611,"briefSummary":612,"conditions":613,"keywords":615,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":264},"100576881","multi-site-trial-of-a-brief-behavioral-intervention-for-dyspnea-in-patients-with-advanced-lung-cancer-100576881","NCT06791057","Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer","BREEZE+","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of advanced lung cancer (i.e., non-small cell lung cancer or small cell lung cancer) or mesothelioma, not being treated with curative intent\n* Self-report at least moderate dyspnea per a rating ≥4 on the validated 0-10 breathlessness item of the Edmonton Symptom Assessment Scale-Revised\n* Functioning independently per an Eastern Cooperative Oncology Group Performance Status ≤2\n* Ability to read and respond to questions in English or Spanish\n* Receiving primary cancer care at one of the participating institutions\n\nExclusion Criteria:\n\n* Significant uncontrolled psychiatric disorder or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the patient's ability to participate in study procedures.",{"count":610,"type":22},420,[59],"Dyspnea, or breathlessness, is one of the most common and distressing symptoms experienced by patients with advanced lung cancer. The purpose of this multi-site trial is to test the effectiveness of a dyspnea intervention (called BREEZE+) that includes three brief nurse-delivered sessions and access to a digital health app that teaches and reinforces patients' use of skills for managing and coping with this highly debilitating symptom. This study will lay the groundwork for a follow-up pragmatic implementation trial integrating BREEZE+ into usual oncology care for patients with advanced lung cancer experiencing dyspnea.",[614,26],"Advanced Lung Cancer",[26,616,617,618],"Breathlessness","Lung Cancer","Behavioral Intervention","2025-09-23",{"date":621,"type":38},"2025-09-24",{"date":623,"type":22},"2026-01-01",{"date":625,"type":22},"2030-03-31",{"name":627,"class":76},"Massachusetts General Hospital",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":634,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":636,"targetDuration":638,"studyType":23,"phases":4,"briefSummary":639,"conditions":640,"keywords":641,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":46},"100600983","evaluation-of-the-impact-of-pleuropulmonary-ultrasound-on-the-diagnosis-of-dyspnea-100600983","NCT07104578","Evaluation of the Impact of Pleuropulmonary Ultrasound on the Diagnosis of Dyspnea","Evaluation of the Impact of Pleuropulmonary Ultrasound Performed by the Emergency Physician on the Diagnosis of Dyspnea in the Prehospital Setting","LU-SMUR","Inclusion Criteria:\n\n* Adult patient\n* Treated by a prehospital emergency medical service\n* For dyspnea with signs of severity, the following are the following:\n\n  * SpO2 \\\u003C 90% in AA or O2 required to maintain SpO2 ≥ 90% and\n  * RR \\> 25 cycles\u002Fmin\n\nExclusion Criteria:\n\n* Opposition to inclusion\n* Need for immediate intubation.",{"count":637,"type":22},40,"52 Weeks","Dyspnea is a subjective symptom perceived by the patient as a sensation of \"breathing discomfort\", \"suffocation\", \"lack of air\" or \"difficulty inhaling or exhaling\". It is a frequent reason for calling for help (8% of calls). The most seriously ill patients require the dispatch of specialized teams capable of initiating respiratory support in order to reduce the morbidity and mortality of these patients. In France, these teams are medicalized by an emergency physician within the Mobile Emergency Resuscitation Services (SMUR). This is only rarely the case outside France, where specialized paramedical teams (\"advanced life support paramedic teams\") can be dispatched. Apart from their role of initiating possible respiratory support, these teams (SMUR or paramedics) can initiate a diagnostic approach and therapeutics related to the suspected origin of dyspnea. However, there are many diagnoses that can cause dyspnea, and the diagnostic process can be complex. The most common diagnoses described in the prehospital population are: bacterial pneumonia, acute heart failure, and exacerbation of COPD or asthma or pulmonary embolism. Each of these diagnoses requires specific drug treatment, guided by international recommendations. Inappropriate treatment of these pathologies (overtreatment or undertreatment) is common and associated with excess intrahospital mortality.\n\nPleuropulmonary ultrasound (PUS) has shown very interesting diagnostic performance in the intrahospital setting for diagnoses of interest in dyspnea. This performance also appears good in the prehospital setting. In the intrahospital setting, PUS appears to improve the diagnostic approach and appropriate treatments for dyspnea. In the prehospital setting, however, data on this subject are scarce or of limited quality according to the most recent meta-analysis, while the use of this technique is becoming increasingly common in standardized patient care. In addition, the most recent work on the subject included patients in a non-medicalized prehospital system. The use of PUS would allow paramedics to increase the rate of appropriate treatment from 14% to 53%. However, the rate of appropriate treatment expected by a medicalized team is expected to be 62%, and the diagnostic performance of physicians in PUS is probably higher than that of paramedics. These data must therefore be consolidated in a French system before being the subject of higher-level recommendations. The systematic use of PUS during prehospital engagement of a SMUR for dyspnea also may improves the rate of appropriate treatment, even in a context of medicalization of the initial care of patients.",[26],[30,642,643],"pleuropulmonary ultrasound","diagnostic","2025-09-22",{"date":646,"type":38},"2025-09-26",{"date":648,"type":38},"2025-08-01",{"date":650,"type":22},"2027-02-01",{"name":577,"class":76},{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":659,"enrollmentInfo":660,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":662,"conditions":663,"keywords":665,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":4},"100606987","cervical-erector-spinae-plane-block-for-dyspnea-in-acute-respiratory-failure-a-prospective-cohort-100606987","NCT07182695","Cervical Erector Spinae Plane Block for Dyspnea in Acute Respiratory Failure: A Prospective Cohort","Effect of Bilateral Cervical Erector Spinae Plane Block on Dyspnea in Patients With Acute Respiratory Failure: A Prospective Single-Cohort Study","Inclusion Criteria:\n\n* ICU admission with acute respiratory failure.\n* Patient or legally authorized representative provides consent.\n* Cervical ESP block performed for dyspnea treatment\n\nExclusion Criteria:\n\n* Infection at block site.\n* Known diaphragm paralysis.\n* Known allergy to local anesthetics.\n* Refusal of consent (patient or representative).","90 Years",{"count":661,"type":22},30,"Dyspnea is common and distressing in patients with acute respiratory failure. In our intensive care unit, some patients receive a cervical erector spinae plane (ESP) block to help relieve dyspnea. This study will observe patients who receive bilateral cervical ESP blocks and measure changes in dyspnea using validated scales at predefined time points over 24 hours. We will also track vital signs, arterial blood gas values, and diaphragm movement on ultrasound.",[664,26],"Acute Respiratory Failure (ARF)",[666,667,668,669],"Cervical ESP block","Diaphragm ultrasound","Intensive care","Ultrasound-guided regional anesthesia","2025-09-12",{"date":672,"type":38},"2025-09-19",{"date":674,"type":22},"2025-09-15",{"date":676,"type":22},"2026-03-15",{"name":678,"class":76},"Hacettepe University",{"id":680,"slug":681,"hasResults":12,"nctId":682,"briefTitle":683,"officialTitle":683,"acronym":684,"eligibilityCriteria":685,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":686,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":688,"conditions":689,"keywords":691,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":700,"locationsCount":4},"100604298","evaluation-of-the-effectiveness-of-the-cardiostory-device-in-distinguishing-heart-failure-from-other-causes-in-patients-presenting-with-dyspnea-100604298","NCT07147699","Evaluation of the Effectiveness of the CardioStory Device in Distinguishing Heart Failure From Other Causes in Patients Presenting With Dyspnea","CARDIOSTORY","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * Recent onset dyspnea (less than 7 days)\n  * Informed consent obtained\n\nExclusion Criteria:\n\n* • Age inferior to 18 years,\n\n  * Severe comorbidity, hemodynamic compromise or immediate need for mechanical ventilation were exclusion criteria.\n  * Dyspnea clearly of traumatic or allergic origin",{"count":687,"type":22},650,"The CARDIOSTORY.TN study is a prospective observational study at Sahloul University Hospital (Sousse, Tunisia) evaluating the CardioStory device for distinguishing heart failure (HF) from other causes of acute dyspnea.\n\nBackground: Dyspnea is common in emergencies, and differentiating cardiac from non-cardiac causes is often delayed by the limits of echocardiography and BNP tests. CardioStory is a rapid (\\~2 minutes), non-invasive tool that measures cardiac filling pressure, a key HF marker.\n\nObjectives:\n\nPrimary: Assess CardioStory's diagnostic accuracy.\n\nSecondary: Compare it with echocardiography and NT-proBNP, evaluate ease of use, and measure time to diagnosis.\n\nMethods:\n\nAdults (≥18) with acute dyspnea (\\\u003C7 days) included; unstable or traumatic\u002Fallergic cases excluded.\n\nCardioStory results will be compared to standard diagnostics.\n\nSample size: 850 patients over 12 months.\n\nOutcome: If accurate, CardioStory could be a fast, practical diagnostic tool for emergency settings.",[26,690],"Heart Failure Acute",[30,692],"acute heart failure","2025-08-28",{"date":695,"type":38},"2025-08-29",{"date":697,"type":22},"2025-09-01",{"date":699,"type":22},"2026-12-01",{"name":701,"class":76},"Hôpital Universitaire Sahloul"]